SMA Combination denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sma combination are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Combination SMA Therapy as Not FDA-Approved

This denial typically means BCBS is asserting that using two disease-modifying SMA agents together — as a combination regimen — is not an FDA-approved indication, even if each individual agent is FDA-approved as a monotherapy. Insurers sometimes apply a strict reading of labeling: if the combination itself is not listed as an approved use in either agent's prescribing information, the plan may categorize the combined use as "off-label" or unapproved and deny on that basis.

## Why This Denial Is Appealable

Off-label use of FDA-approved drugs is a well-established, legally protected element of medical practice, and many state laws and federal guidance documents require insurers to cover off-label use when supported by published clinical evidence and recognized compendia (such as those listed in Medicare's off-label coverage framework). If your physician can document that combination SMA therapy is supported by peer-reviewed evidence and addressed in relevant expert guidelines, this denial can be challenged on multiple grounds.

## Federal Appeal Framework

• Internal appeal (Level 1): File a written appeal with clinical literature support and a prescriber medical-necessity letter explaining the evidence base for combination use.
• Compendia and literature argument: Reference the applicable recognized drug compendia and professional society guidance. Many states require insurers to cover off-label use referenced in approved compendia.
• External review (ACA §2719): After internal exhaustion or final adverse determination, you have the right to independent external review. The federal window is generally four months from the adverse determination letter date; check your specific deadline.
• Expedited review: Available if the standard timeline poses serious health risk.
• State insurance commissioner: If BCBS is a fully-insured plan, your state's insurance commissioner can receive a complaint if the plan violates state off-label coverage mandates.

## Documentation to Gather

1. FDA labeling for each agent: Print the current FDA-approved prescribing information for each drug. Identify the approved indication and confirm it covers the patient's SMA type and age. 2. Clinical literature summary: Your physician should compile peer-reviewed publications and any expert consensus statements supporting combination use. The appeal letter should cite these — not invent statistics, but reference their existence and source. 3. Recognized compendia listings: Check whether combination SMA therapy appears in recognized compendia (AHFS, Micromedex, etc.) and include that documentation. 4. Professional society guidance: Obtain the relevant position statement or guideline from the applicable neuromuscular or rare-disease society. 5. Prescriber medical-necessity letter: Signed letter from the treating neuromuscular specialist explaining why combination therapy is appropriate for this patient, grounded in the published evidence base.

## Criteria-Mapping Structure

Ask BCBS to identify exactly which FDA-approval requirement they applied and provide the policy text. Then map:

| Plan's Stated Basis for Denial | Your Counter-Evidence | |---|---| | Combination not in FDA labeling | Reference to compendia listing or society guideline | | Off-label use not covered | State law / plan off-label coverage provision | | No peer-reviewed support | Literature summary compiled by treating physician | | Experimental classification | Distinction from experimental — approved agents, existing evidence base |

Address each stated basis point-by-point in your appeal letter.